<DOC>
	<DOCNO>NCT03097848</DOCNO>
	<brief_summary>Radiofrequency ablation popular treatment recurrent hepatocellular carcinoma ( HCC ) , still high recurrence . Sorafenib neo-adjuvant therapy combination RFA report yet . There 's theoretical advantage combination . Hence study efficacy safety pre-administrative Sorafenib Latter radiofrequency ablation ( RFA ) Recurrent HCC test multicenter prospective cohort study .</brief_summary>
	<brief_title>Efficacy Safety Sorafenib Adjuvant Latter Radiofrequency Ablation Recurrent Hepatocellular Carcinoma</brief_title>
	<detailed_description>Radiofrequency ablation popular treatment recurrent hepatocellular carcinoma ( HCC ) , still high recurrence . Sorafenib neo-adjuvant therapy combination RFA report yet . There 's theoretical advantage combination . Hence study efficacy safety pre-administrative Sorafenib Latter radiofrequency ablation ( RFA ) Recurrent HCC test multicenter prospective cohort study . Eligible case assign experimental group control group . For experiment group , sorafenib tablet give two week , perform radiofrequency ablation . For control group , RFA perform immediately .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Aged 18 75 year old Without gender restriction With favorable liver function ChildPugh A B No contraindication RFA anesthesia Diagnosed Recurrent HCC Signed informed consent . Cancer thrombosis major vessels/ extrahepatic metastasis Uncontrollable ascites variceal bleed Impairment liver function Severe disorder vital organ Accompanied tumor infectious disease except hepatitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>